Does amiodarone or an implantable cardioverter-defibrillator reduce overall mortality in patients with NYHA class II or III CHF and LVEF of 35 percent or less?
In patients with symptomatic heart failure and reduced ejection fraction, single-lead shock-only ICD therapy reduces mortality by 23%, whereas amiodarone provides no survival benefit.
In patients with NYHA class II or III CHF and LVEF of 35 percent or less, amiodarone has no favorable effect on survival, whereas single-lead, shock-only ICD therapy reduces overall mortality by 23 percent.
Bardy et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: